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Abstract: Methylxanthines (MTX) are purine derived xanthine derivatives. Whereas naturally
occurring methylxanthines like caffeine, theophylline or theobromine are widely consumed in food,
several synthetic but also non-synthetic methylxanthines are used as pharmaceuticals, in particular in
treating airway constrictions. Besides the well-established bronchoprotective effects, methylxanthines
are also known to have anti-inflammatory and anti-oxidative properties, mediate changes in lipid
homeostasis and have neuroprotective effects. Known molecular mechanisms include adenosine
receptor antagonism, phosphodiesterase inhibition, effects on the cholinergic system, wnt signaling,
histone deacetylase activation and gene regulation. By affecting several pathways associated with
neurodegenerative diseases via different pleiotropic mechanisms and due to its moderate side
effects, intake of methylxanthines have been suggested to be an interesting approach in dealing with
neurodegeneration. Especially in the past years, the impact of methylxanthines in neurodegenerative
diseases has been extensively studied and several new aspects have been elucidated. In this review
we summarize the findings of methylxanthines linked to Alzheimer´s disease, Parkinson’s disease
and Multiple Sclerosis since 2017, focusing on epidemiological and clinical studies and addressing
the underlying molecular mechanisms in cell culture experiments and animal studies in order to
assess the neuroprotective potential of methylxanthines in these diseases.
Keywords: methylxanthines; caffeine; theobromine; theophylline; pentoxifylline; propentofylline;
istradefylline; Alzheimer´s disease; Parkinson´s disease; Multiple Sclerosis
1. Introduction
This review summarizes on the latest findings of the relationship between methylxan-
thines and neurodegenerative diseases, especially Alzheimer’s disease (AD), Parkinson´s
disease (PD) and Multiple Sclerosis (MS). These multifactorial disorders share several
common histopathological hallmarks and mechanisms like neuronal cell loss linked to
gliosis, misfolding and accumulation of proteins, oxidative stress and neuroinflammation.
In case of AD, disease progression is strongly associated with Aβ peptide generation
and aggregation, associated with pathological extracellular and intracellular filamentous
deposits, hyperphosphorylated tau proteins, neuroinflammation and synaptic loss. PD
is characterized by dopaminergic neurodegeneration and accumulation of α-synuclein in
Lewy bodies. Concerning MS, neuroinflammatory processes leading to demyelination of
neurons are in the focus of the disease.
Numerous studies have been performed to address the question of whether xanthine
derivatives like caffeine and theobromine have beneficial properties in respect to the
characteristic histopathological changes that occur in the above-mentioned diseases and to
cognitive decline. Although the outcome of the clinical studies, especially for AD, were
heterogeneous [1], some mechanisms were identified, showing how methylated xanthine
derivatives could protect against neuronal damage.
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In general, in physiological concentrations, achieved for example by coffee consump-
tion or by intake of methylxanthine containing beverages, methylxanthines act as antago-
nists of the adenosine receptor (AR), histone deacetylase activator or antioxidant. Affecting
these pathways, xanthine derivatives are able to modulate molecular mechanisms associ-
ated with neurodegenerative diseases like accumulation of misfolded proteins, oxidative
stress and neuroinflammation. Interestingly, in particular the beneficial role of adenosine
receptor antagonists in the treatment of neurodegenerative diseases has become more and
more apparent in the last years [2–5].
In supraphysiological concentrations, which can be reached for example, by intake of
methylxanthines as pharmaceuticals, additional mechanisms like inhibition of phospho-
diesterases and high-affinity ATP-dependent cyclic nucleotide transporters are reported,
also contributing to neuroprotective properties of methylxanthines [6]. Besides the above-
mentioned properties of xanthine derivatives, further mechanisms were suggested or
excluded in the last years and are summarized in detail below together with new clinical
trials addressing these issues (also see figures and tables).
2. Alzheimer’s Disease
2.1. Epidemiological and Clinical Studies
In the past four years, several new clinical and epidemiological studies were published
examining the influence of caffeine or other methylxanthines on cognitive performance in
respect to AD, see Table 1.
Jee Wook Kim and colleagues analyzed the relationship between lifetime coffee intake
and AD biomarkers in the human brain using neuroimaging techniques like positron emis-
sion tomography (PET), magnetic resonance imaging scans and clinical assessment. The
study included 411 participants with an inclusion criterion for patients already suffering
from mild cognitive impairment (MCI) but without a diagnosis of dementia. Study partici-
pants were divided into high and low/no coffee consumer: 269 participants, consuming no
coffee or <2 cups/day, and 142 participants stated to drink two or more than two cups per
day, reflecting higher coffee intake. The authors reported that a higher lifetime coffee intake
was significantly associated with a reduced pathological cerebral amyloid deposition and
could therefore be linked to a lowered risk for AD or cognitive decline even after controlling
for potential cofounders. Besides the association of coffee intake with reduced amyloid de-
position, no correlation between coffee intake and AD associated glucose hypometabolism,
atrophy or cortical thickness and cerebral white matter hyperintensities were detected [7].
This study is in line with older results obtained by transgenic mouse models or animals
revealing a decreased Aβ concentration [8,9]. Interestingly, this study also revealed that
the effect was more pronounced in long-term coffee drinkers suggesting that the positive
effects of higher coffee intake against Aβ pathology involve more chronic effects which
are associated with a regular long-term exposure rather than a short-term effect of caffeine.
These results might help to explain why some previous studies including participants with
shorter caffeine exposure showed weak or no correlation of caffeine with cognitive decline
or amyloid burden, emphasizing that not only the caffeine concentration but also duration
of exposure plays a critical role for the beneficial effects of methylxanthines in AD.
In this context a new meta-analysis of eight observational prospective studies from
Larsson and Orsini should be noticed. No statistically significant association between
coffee consumption and risk of dementia were detected by the authors. The 95% confidence
interval of dementia for one cup coffee/day was 0.92, two cups/day 0.90, three cups/day
0.93, four cups/day 1.01 and five cups/day 1.11. In line with the authors, it has to be
mentioned that especially over a long time, coffee consumption may vary and is hard
to be exactly estimated. Moreover, three studies showing effects of coffee consumption
on AD risk were not included because they used different quantitative categories of
coffee consumption [10–13]. Another interesting aspect is revealed by a recent study
from Iranpour and colleagues analyzing data from the National Health and Nutrition
Examination Survey (NHANES) including 1440 participants older than 60 years [14]. By
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applying different cognitive tests, the authors reported a weak positive relation of high
caffeine intake with cognitive function. Importantly the correlation was stronger amongst
males than females emphasizing a potential need of subgroup-analysis besides combining
studies in meta-analysis to obtain large but probably even more heterogeneous cohorts. In
summary, in respect to dose dependency, a correlation between coffee consumption and
AD risk is still controversial and can currently not be answered without uncertainty in
absence of further studies.
2.1.1. Are the Positive Effects due to Caffeine or Other Compounds in Coffee?
Besides caffeine, coffee contains several biological compounds known to be biolog-
ically active—such as phenylindanes or molecules produced during roasting of coffee
beans [15,16]. Therefore, it is difficult to answer the question of whether the potential
positive observed effects are due to caffeine or other substances. Addressing exactly this
important question, Xue Dong and colleagues analyzed in their study the association of
coffee, caffeinated coffee, decaffeinated coffee and caffeine intake from coffee with cognitive
performance. CERAD (Consortium to Establish a Registry for Alzheimer´s Disease) test
and DSST (Digit Symbol Substitution Test) were performed with over 2500 participants
from the NHANES aged 60 years or older without any diagnosis of AD. Significant associ-
ations with cognitive performance were reported for coffee, caffeinated coffee and caffeine
from coffee, but not for decaffeinated coffee [17], underlining the important role of the
methylxanthine caffeine in coffee. However, as older studies could also show beneficial
effects of other compounds in coffee—besides caffeine—this result should emphasize the
impact of caffeine but does not rule out that other substances might contribute, especially
in combination with caffeine, to a protective effect as well [18,19].
2.1.2. The Effect of Other Methylxanthines on Alzheimer’s Disease
Besides caffeine, several other methylxanthines are known that have potential pro-
tective effects in respect to their molecular mechanism. However, very little is known
about their potential protective function in respect to AD in clinical studies or data ob-
tained from human samples. De Leeuw investigated the association of different nutritional
biomarkers with clinical progression in patients with cognitive decline. Theobromine
revealed to be increased in a subgroup of patients with lower Aβ42 level but also higher
total and phosphorylated tau level. In addition, high theobromine levels were found to be
associated with cognitive decline in mild cognitive impairment (MCI) patients [20]. At first
glance, these results might point towards a negative impact of methylxanthines in disease
progression. However, it has to be taken into consideration, that caffeine is metabolized in
the liver to theobromine. A faster or altered metabolization rate of caffeine might result
in an increase in theobromine but in a decreased caffeine level. Theobromine compared
to caffeine has been shown to have a lower anti-amyloidogenic potential [21]. Therefore,
the association of increased theobromine with cognitive decline might be influenced by
the faster degradation of caffeine resulting in lower caffeine levels. However, as caffeine
is not studied in this paper this potential explanation is speculative. Nevertheless, in
line with this argumentation, a recent article from Mullins and colleagues discussed if
genome-wide single nucleotide polymorphism (SNP) data can help to predict the individ-
ual response to dietary interventions. The CYP1A2 gene encodingcytochrome P450 1A2,
which is responsible for approximately 95% of caffeine metabolization and thirteen SNPs
are associated with this gene. One of these SNPs (rs762551) influences the sensitivity for
caffeine and how fast it gets metabolized [22]. Unfortunately, it is unknown whether this
SNP is associated with AD, but undoubtedly—this SNP in the CYP1A2 gene having an
impact on caffeine intake might explain the heterogeneous results of clinical studies and
should be taken into consideration for further clinical trials, since SNP data are nowadays
quickly and inexpensively acquired. Therefore, in clinical studies CYP1A2 variants have
to be considered as an additional important factor highly affecting the pharmacokinetic
of methylxanthines. Importantly, the pharmacokinetic of methylxanthines can be further
Nutrients 2021, 13, 803 4 of 18
influenced by lifestyle or dietary habits. For example, caffeine consumption combined
with smoking cessation has been reported to be associated with more than two times
increased caffeine plasma levels that could even induce caffeine toxicity symptoms [23].
In summary, the lack of knowledge of the methylxanthine plasma levels or the lifestyle
habits which interfere with the pharmacokinetics of methylxanthines, and the additional
analysis of CYP1A2 variants, makes it hard to estimate the potency of methylxanthines in
treating or preventing neurodegenerative diseases and should be considered as a caveat in
interpreting previous studies.
Table 1. Summary of recent clinical studies investigating the relationship between methylxanthines and Alzheimer´s
disease (AD). n: sample size; CSF: cerebrospinal fluid; CRP: c-reactive protein.
Author Year Type of Study/n Substance Outcome
Kim et al. [7] 2019
clinical trial/
411 healthy participants (142
coffee drinkers and 269
reference participants)
coffee
association of coffee intake
with reduced amyloid
deposition






no evidence for a relationship
between coffee-consumption
and risk of dementia or AD
Iranpour et al. [14] 2019 clinical trial/1440 participants caffeine
weak positive relation of high
caffeine intake with cognitive
function
Dong et al. [17] 2020 clinical trial/2500 participants caffeine
significant associations with
cognitive performance for
coffee, caffeinated coffee and
caffeine from coffee, but not for
decaffeinated coffee
Leeuw et al. [20] 2020 longitudinal study/299 participants theobromine
high levels of theobromine
detected in CSF are associated
with clinical progression to
dementia
Sanders et al. [6] 2020
















coffee and CRP levels when
analyzing the three studies
with the largest sample size
but no significant association
when combining all studies




Moreover, synthetic methylxanthines are an interesting substance class which might
be suitable to treat or prevent AD, because of their capability to act as phosphodiesterase
inhibitors. A recent systematic review of clinical trials, epidemiology and meta-analyses
reported propentofylline as the only phosphodiesterase inhibitor having completed efficacy-
testing clinical trials showing improvement of cognition and dementia severity in mild-
to-moderate AD patients. Propentofylline was found to be the most effective inhibitor
out of phosphodiesterase-inhibiting xanthine derivatives by inhibiting several phospho-
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diesterase isoforms, especially phosphodiesterase 2 and 4. The authors therefore suggest
a co-treatment of propentofylline with the phosphodiesterase 5 inhibitor sildenafil for
prevention or treatment of AD [6]. Based on these data further clinical trials analyzing
the effect of this synthetic methylated xanthine on AD symptoms and severity should
be performed.
It has to be considered that clinical studies could have limitations like un-representative
sample populations, implications of confounds or personal motivation of the participants
for self-reporting of their coffee consumption. Other interesting points are the individual
caffeine sensitivity and the above mentioned pharmacokinetic of methylxanthines.
2.2. Animal Studies/Molecular Pathways
Concerning the uptake of caffeine, an animal study from Liang Jin and colleagues
shows that intestinal permeability and oral absorption of caffeine were not affected in a
mouse model of familial AD. They reported that plasma caffeine concentration as well
as total brain exposure did not differ between wildtype and APP/PS1 mice after oral ad-
ministration. APP/PS1 mice contain human transgenes for both APP bearing the Swedish
mutation and PSEN1 containing the L166P mutation, therefore representing a transgenic
mouse model that overproduces Aβ and that is often used to study the neuropathologic
mechanisms of AD as well as the therapeutic effects of drugs on AD [26]. In line with
this, the authors demonstrated in a previous study, that the abundance of intestinal and
hepatic Cyp1a2 was not different in APP/PS1 mice in comparison to wildtype mice [27].
These data suggest caffeine as potential therapy for AD, since its uptake is not impaired in
patients suffering from this neurodegenerative disease. Another animal study, performed
by Zappettini and colleagues, used a mouse model of AD-like Tau pathology (THY-Tau22
transgenic mice) for investigation of the long-term consequences of early life exposure to
caffeine during pregnancy. Their findings suggest that Tau pathology related pathological
traits appear earlier in the offspring of caffeine exposed mice and therefore suggest caffeine
exposure during pregnancy as a risk factor for early onset AD like pathology [28].
In addition to caffeine, the neuroprotective effects of its metabolite theobromine were
also analyzed in animal studies. Yoneda and colleagues reported that orally administered
theobromine (0.05% for 30 days) is detectable in plasma and cerebral cortex in wild type
mice. (The utilized mouse strain here was C57BL/6NCr mice, the nomenclature of these
mice is due solely to their origin, since after establishing the substrain C57BL/6 at The
Jackson Laboratory the sublines C57BL/6N and C57BL/6J were separated and Cr stands for
Charles River because this company acquired their breeding colonies in 1974 [29]). It can act
as phosphodiesterase inhibitor in the brain and enhances cAMP/CREB/BDNF pathways
in a way that supports cell survival and neuronal functions. Moreover, the theobromine-fed
mice showed better performances on a three-lever motor learning task [30]. These findings
suggest a beneficial influence of cacao products on learning and memory.
In the case of the adenosine A2 receptor (A2AR) antagonist istradefylline, a phar-
maceutic that is approved for PD in Japan (for detailed information see later), an animal
study performed by Orr and colleagues investigated the ability of this reagent to enhance
cognitive functions in aging mice with AD-like amyloid plaque pathology. The authors
reported increased spatial memory and habituation in APP transgenic mice treated with
low doses of istradefylline (≤10 mg/kg/day) and underline the importance of further
investigations of this adenosine receptor antagonist as potential therapeutic approach for
AD or other neurodegenerative diseases besides PD [31]. In this context, a recent in vitro
study from Franco and colleagues suggests that antagonists of A2AR affects the function of
N-methyl D-aspartate ionotropic glutamate receptors (NMDAR), since A2AR activation
leads to higher NMDAR functionality in neurons [32].
In the past years several experimental studies were performed to elucidate the molec-
ular mechanisms that underlie the observed beneficial effects of methylxanthines like
caffeine in AD. Gastaldo and colleagues examined in their study if food ingredients (among
others caffeine) are able to affect Aβ peptide aggregation in AD through an indirect,
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membrane-mediated pathway, since membranes are known to play a crucial role in early
stages of peptide aggregation. The authors used synthetic brain membranes to analyze
the influence of caffeine on size and volume fraction of aggregates consisting of cross-β
sheets of the membrane active fragment Aβ25-35. Caffeine was reported to spontaneously
partition into the membranes in the first 150 ns of the molecular dynamics simulation
and found to mainly position in the head-tail interface of the membranes—and some also
temporarily inside the hydrophobic core. The Aβ25-35 peptides were found via microscopy
to form pronounced amyloid fibrils, located on the top of the membranes in the presence
of caffeine. Moreover, using X-ray diffraction they found that caffeine leads to membrane
thickening and to a decrease in membrane fluidity and in presence of the Aβ25-35 peptides
an increase in local membrane curvature was reported, which is likely induced by the
formation of extracellular Aβ aggregates and fibrils. Additionally, they found in their
UV-visible spectroscopy studies using thioflavin T, a significant increase in the fluorescent
signal of β-sheets at 420 nm after addition of caffeine [33]. Similar results regarding the
influence of caffeine on membranes were obtained in one of the authors’ earlier studies [34].
In respect to caffeine and Aβ peptides, Gupta and colleagues reported as a result of their
molecular dynamics simulations a disorganization of cross-β structures of Aβ17-42 fibrils
in the presence of caffeine. This destabilization effect might further inhibit the formation
of aggregates [35]. In respect to Aβ homeostasis, Janitschke and colleagues examined
the effects of the methylxanthines caffeine, theobromine, theophylline, pentoxifylline and
propentofylline in human neuroblastoma cells. They concluded that the analyzed xanthine
derivatives reduce the levels of Aβ via pleiotropic mechanisms by shifting the processing of
the amyloid precursor protein from the amyloidogenic to the non-amyloidogenic pathway
via influencing protein stabilities and gene expressions as well as affecting the involved
secretases directly. Moreover, these methylxanthines decrease oxidative stress, levels of
cholesterol and aggregation of Aβ1-42 in SH-SY5Y neuroblastoma cells [21].
Another pathway, by which caffeine could mediate its pharmacological activity, is
the cholinergic system. In this context, Fabiani and colleagues used single channel record-
ings and fluorescent measurements to examine the influence of caffeine on the nicotinic
acetylcholine receptor (AChR). Their results show that caffeine acts as a partial agonist and
an ion channel blocker at neuronal α7 and muscle nicotinic receptors (AChR) at different
concentrations and suggest this methylxanthine as a multitarget-directed drug for the treat-
ment of AD [36]. Interestingly, Kumar and colleagues screened more than 600 molecules
of natural origin for their ability to modulate acetylcholine metabolism. They found that
caffeine has a comparable AChE inhibitory potential to donezepil, a commonly used drug
to treat mild to moderate dementia. Moreover, caffeine shows no neurotoxicity in primary
(E18) hippocampal neurons but significantly improves neuronal survival and protects from
neurodegeneration [37].
For the efficiency of caffeine its distribution to and in the brain is highly important. It
is important to mention that ATP-binding cassette (ABC) transporters in the brain can be
affected and therefore might have an impact on methylxanthine distribution in the brain
under pathological conditions [38]. In addition, it has been shown that caffeine is able
to inhibit ABCC4 and ABCC5 with affinities of similar magnitude as for the adenosine
receptor and thereby might diminish its efflux from the brain [39].
The anti-inflammatory and antioxidant potential of caffeine was analyzed by Badshah
and colleagues in an animal study using lipopolysaccharide (LPS)-induced oxidative stress
and neuroinflammation. LPS was identified as a Toll-like receptor 4 (TLR-4) ligand, primar-
ily expressed in the central nervous system. Activation of TLR-4 leads to the production of
proinflammatory cytokines, key mediators of the neuro-inflammatory process [40]. The
authors reported upregulated expression levels of nuclear factor erythroid-2-related factor
2 and enzyme hemeoxygenase 1, two endogenous antioxidant regulators, and significantly
downregulated expression levels of toll-like receptor 4, phosphor-nuclear factor kappa
B and phosphor-c-jun n-terminal kinase in the LPS-injected mouse model treated with
30 mg/kg/day caffeine intraperitoneally for four weeks. Accordingly, this study was able
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to show—by using Western blot, immunofluorescence studies and biochemical assays—
that caffeine prevents LPS-induced oxidative stress in the mouse brain and suppresses
inflammatory mediators simultaneously [41]. The same authors showed in a second study
using in vitro (HT-22 and BV-2 cells) and in vivo (B57BL/6N mice) models, reducing effects
of caffeine in regard to reactive oxygen species, lipid peroxidation and inflammatory medi-
ators. Cadmium-induced cognitive deficits, neuronal loss or synaptic dysfunction were
rescued by caffeine in their mouse model. On a molecular level the neuroprotective effects
of caffeine are exerted via regulation of nuclear factor-2 erythroid-2 and nuclear factor-
κB [42]. Moreover, neuroinflammation and Aβ may cause neuronal death by activating
the complement system. A potential impact of complement- and C-reactive protein (CRP)-
mediated neuronal death in AD has already been discussed in previous literature. Fischer
and colleagues reported increased levels of complement component 1q (C1q) in the frontal
cortex of patients suffering from AD [43]. In human AD/stroke patients, a co-localization
of monomeric CRP (mCRP) with Aβ plaques, tau-like fibrils and insulin receptor substrate
1 (IRS-1)/Phospho-Tau positive neurons was reported, and the authors suggested mCRP
may be responsible for promoting dementia after ischemia [44]. Importantly, it has been
shown that coffee consumption can reduce CRP levels and therefore reduce inflammation,
which has been analyzed in a dose response meta-analysis including eleven studies and
61,047 participants. Analysis of the three studies with the largest sample sizes shows a
statistically significant association between coffee and CRP levels. However, by combin-
ing all studies, no significant associations were found in a dose-response meta-analysis,
indicating a further need to investigate these inconsistent associations [24]. In line with the
reported slightly anti-inflammatory effects of coffee, Rodas and colleagues showed in their
recent study that caffeine intake is a negative predictor of CRP. They analyzed the effect of
regular caffeine intake in 244 healthy participants aged 18–55 years [25].
Recently, another additional mechanism by which caffeine might exert its potential
therapeutic benefits in AD has been suggested by Zhao and colleagues [45]. In the pres-
ence of caffeine, Wnt signaling was found to be upregulated. Caffeine can bind to and
inhibit the activity of notum, a hydrolase which inhibits Wnt signaling via enzymatic
delipidation of Wnt ligands. Restoration of Wnt signaling is discussed to be beneficial in
AD pathologies, since this pathway is essential for neuronal differentiation, development,
adult neurogenesis and neural stem cell maintenance. Interestingly, only caffeine, but
not its demethylated metabolites paraxanthine, theobromine or theophylline exerts this
inhibitory property. Using structure analysis, the authors were able to show that caffeine
binds at the enzymatic pocket and overlapped the position of notum´s natural substrate
palmitoleic lipid [45]. The relatively low inhibitory potency of caffeine (IC50 19 µM) indi-
cates that in adults consuming moderate amounts of three or four cups of coffee per day,
resulting in plasma concentrations of about 15 µM [46], physiological notum inhibition
seems unlikely. But in the case of using caffeine as a therapeutic medicine, plasma levels of
150 µM were obtained [47].
Moreover, it is discussed that caffeine in physiological concentrations mediates its
neuroprotective effects via its inhibitory interactions with adenosine receptors and thereby
increases the concentration of adenosine, known to have neuromodulatory properties.
Nabbi-Schroeter and colleagues investigated the influence of long-term caffeine consump-
tion (30 mg/kg/day for 84 days in drinking water) on the adenosine A1 receptor (A1AR)
using small animal positron emission tomography and the highly selective radioligand
[18F]CPFPX in the brain of Sprague-Dawley rats. The selected dose of caffeine in this study
corresponds to a human consumption of four to five cups of coffee per day, which is a
common daily intake in industrialized countries. The authors reported no long-persistent
upregulation of functionally available A1ARs in vivo under their experimental conditions
of chronic caffeine intake, and based on this, they excluded this mechanism as a molecular
basis for mediating the neuroprotective effects reported for this methylated xanthine [48]. In
regard to the A1AR, Mendiola-Precoma and colleagues reported in their study—examining
the effects of a cholesterol-enriched diet on cognitive processes in a rat model—that the
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caffeine metabolite theobromine was able to restore A1 receptor levels, which were reduced
as a consequence of the diet. Moreover, theobromine showed prophylactic neuroprotection
against damage to cognitive functions and levels of Aβ when 30 mg/L were added to
drinking water. The authors suggest that the reducing Aβ effect could be mediated by
the antioxidant and anti-inflammatory capacities of theobromine via decreased SOD1 and
NFκB levels [49]. Moreover, theobromine isonucleotide analogs were synthesized and eval-
uated as active compounds in the inhibition of cholinesterases, since their low cytotoxicity
makes them interesting as therapeutic molecules for AD [50]. Recently, Ciaramelli and
colleagues reported theobromine and catechins as the chemical components of cocoa that
hinder Aβ peptide aggregation and toxicity. They analyzed the contents of Lavado cocoa
in respect to their anti-amyloidogenic properties using NMR spectroscopy, preparative
reversed-phase chromatography, atomic force microscopy and biochemical and cell as-
says in a human neuroblastoma SH-SY5Y cell line, which is commonly used to elucidate
underlying mechanisms in respect to AD [51].
Recently, methylxanthines were reported to influence the expression of genes linked
to pathways involved in processes like oxidative stress, lipid homeostasis, signal transduc-
tion, transcriptional regulation, and neuronal function, all known to be influenced in the
pathophysiology of AD, by Janitschke and colleagues. In their profiling study on a human
neuroblastoma cell line, they found that caffeine shows different or inverse effects on gene
regulation compared to the other analyzed methylxanthines theobromine, theophylline,
pentoxifylline and propentofylline [52]. In line with the outcome of the above-mentioned
studies, summarized in Figure 1 and Table 2, significant differences between the individual
methylxanthines were detected, further complicating a prediction of neuroprotective effects
of other methylxanthines by referring to caffeine.
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methylxanthines in respect to Alzheimer´s disease.
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Table 2. Summary of recent animal and cell culture studies investigating the relationship between methylxanthines and
Alzheimer´s disease (AD). FAD: familial Alzheimer´s disease. A1AR: adenosine A1 receptor. A2AR: adenosine A2 receptor.
LPS: lipopolysaccharide.
Author Year Used Model Substance Outcome
Liang Jin et al. [27] 2020 APP/PS1 mice caffeine
intestinal permeability and oral
absorption were not affected in
the FAD mouse model
Zappettini et al. [28] 2019 THY-Tau22 mice caffeine
consumption during pregnancy
accelerates the development of
cognitive deficits in offspring in
a model of tauopathy
Yoneda et al. [30] 2017 C57BL/6NCr mice theobromine
up-regulated cerebral
brain-derived neurotrophic
factor and facilitated motor
learning
Orr
et al. [31] 2018
mice with AD-like amyloid
plaque pathology istradefylline reduced memory deficits
Franco
et al. [32] 2020
primary cultures of neurons and




high levels of theobromine
detected in CSF are associated
with clinical progression to
dementia
Gastaldo et al. [33] 2020 synthetic brain membranes caffeine
caffeine is able to affect Aβ
peptide aggregation in AD
through a membrane-mediated
pathway
Gupta et al. [35] 2019 in silico study caffeine
disorganization of cross-β
structures of Aβ17-42 fibrils in
the presence of caffeine










levels and Aβ aggregation
Fabiani et al. [36] 2018
AchR-rich membrane fragments
from T. californica and HEK293
cells
caffeine pharmacological activity ofcaffeine in the cholinergic system
Kumar et al. [37] 2019 primary hippocampal neurons caffeine
AchE inhibitory potential,
improved neuronal survival and
protection from
neurodegeneration
Badshah et al. [41] 2019 LPS-injected mouse model caffeine
prevention of LPS-induced
oxidative stress and suppression
of inflammatory mediators





regulating nrf-2/ho-1 in vivo
and in vitro
Zhao et al. [45] 2020 HEK293 cells caffeine inhibition of notum activity bybinding at the catalytic pocket
Nabbi-Schroeter et al.
[48] 2018 Sprague-Dawley rats caffeine
no long-persistent upregulation
of functionally available A1Ars
under their conditions
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Table 2. Cont.
Author Year Used Model Substance Outcome
Mendiola-Precoma




Ciaramelli et al. [51] 2021 SH-SY5Y cells theobromine theobromine hinders Aβ peptideaggregation and toxicity








of caffeine compared to the other
tested MTX on AD-related genes
3. Parkinson’s Disease
3.1. Epidemiological and Clinical Studies
Parkinson´s disease (PD) is one of the most common neurodegenerative diseases
characterized by a loss of dopaminergic-neurons in the substantia nigra and accumulation
of misfolded α-synuclein protein aggregates in Lewy bodies. Leading symptoms of PD
are bradykinesia or akinesia with rest tremor, postural instability or rigor. Additionally,
patients suffering from PD show a broad range of non-motor symptoms differing in early
and late-stage symptoms, e.g., obstipation and dementia. Despite an unknown etiology of
PD, many risk factors such as age, male gender, environmental factors, intestinal inflamma-
tion, and genetics are described [53,54]. Besides the known risk factors it is discussed that
nutrition may be associated with increased (dairy products) or decreased (phytochemicals,
Omega-3 fatty acids, tea) risk or progression in PD [55]. Multiple epidemiological studies
could already demonstrate an inverse association between coffee drinking and PD and
thereby suggest a link to caffeine, and consequently methylxanthines, as A2A receptor
antagonists [56–58]. Recent studies have confirmed this association (for an overview see
Table 3). Bakshi et al. found a significantly lower caffeine intake, determined through
questionnaire, in idiopathic PD patients compared to control group from the Harvard
Biomarkers Study cohort with 369 cases of PD and 197 healthy controls [59]. In a study
from Fujimaki et al., the authors investigated serum from 108 patients with PD by liquid
chromatography-mass spectrometry (LC-MS) compared to 31 age-matched healthy control
participants and found significantly lowered serum levels of not only caffeine, but also
its downstream products like theophylline, theobromine and paraxanthine [60]. Crotty
et al. demonstrated similar results in a recent metabolomics study showing a significantly
lower plasma and CSF concentration of caffeine (71% lower) and its degradation products,
e.g., paraxanthine and theophylline (57%, 56% lower), in PD patients versus control group
measured via LC-MS. Subgroup analysis of carriers of the LRRK2 mutation, a mutation in
the leucine-rich repeat kinase 2 gene (known for an increased risk for sporadic PD) [61],
revealed an even greater decrease of plasma caffeine level by 76% for PD LRRK2 mutation
carriers compared to healthy LRRK2 carriers [62]. Ohmichi et al. found similar results for
the methylxanthine analogue theophylline and confirmed a significantly lower plasma
concentration in patients with PD versus an age-matched control group [63]. A recent
meta-analysis by Hong et al., which included 13 studies in total, showed that for healthy
individuals, caffeine consumption results in a significantly lower risk of developing PD
specific symptoms (HR = 0.797, 95% CI: 0.748–0.849, p < 0.001, I2: ~ 15.41%, 9/13 stud-
ies). Furthermore, a significant deceleration of PD progression among early-stage PD
individuals with higher caffeine consumption was found (HR = 0.834, 95% CI = 0.707–0.984,
p = 0.03, I2: ~39.7%, 4/13 studies) [64]. Another interesting recent study, carried out by
Maclagan et al., used a computational approach to rank 620 drugs with the ability to
inhibit α-synuclein aggregation. They examined associations between the top 15 drugs
in case-control validation study by using health administrative databases. Their logistic
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regression models found that patients exposed to methylxanthines, especially the syn-
thetic pentoxifylline (PTX) and the natural occurring theophylline, were associated with
decreased odds of occurrence of PD. Additionally longer durations of PTX administration
revealed a trend towards dose-response [65]. One modified methylxanthine, istradefylline
(ISD), has been used to decrease daily “off episodes”, a state where symptoms recur when
the effect of L-DOPA weakens, in PD patients. ISD was approved first in Japan in May
2013 and by the FDA in the US in 2019 [66]. A meta-analysis including six studies revealed
that treatment with ISD 40 mg/day decreased the duration of “off episodes” and enhanced
the motor symptoms of PD patients. Similar effects could be found for 20 mg/day. ISD
treatment revealed no significant effect on adverse effects. In summary the meta-analysis
showed that ISD 20mg and 40mg both improved the unified Parkinson’s disease rating
scale III (UPDRS) [67].
Table 3. Summary of recent clinical studies investigating the relationship between methylxanthines and Parkinson´s Disease
(PD). n: sample size; CSF: cerebrospinal fluid.
Author Year Type of Study/n Substance Outcome
Bakshi et al. [59] 2020
cross sectional, case-control/197
healthy control vs. 369
idiopathic PD patients
caffeine, urate
the authors found a robust
inverse association between
idiopathic PD and caffeine
intake and urate plasma levels
Fujimaki et al. [60] 2018
clinical trial/31 healthy control







absolute lower levels of caffeine
and metabolites were found to
be a promising biomarker for
early PD
Crotty
et al. [62] 2020
clinical trial/samples from
“23andMe” study, LRRK2
longitudinal study and LRRK2








significantly lower plasma and
CSF levels of caffeine and
downstream metabolites in PD
patients, even more in LRRK2
mutation carriers
Ohmichi et al. [63] 2018 clinical trial/31 PD patients vs.33 age-matched controls theophylline
theophylline serum levels were
significantly lower in PD
patients compared to control
Hong
et al. [64] 2020
meta-analysis/13 studies (9
healthy cohort, 4 PD cohort) caffeine
caffeine consumption resulted in
a significantly lower rate of PD
Maclagan et al. [65] 2020
computational &
pharmacoepidemiologic study
ranking 620 drugs, case-control





the authors state, that





et al. [67] 2017 meta-analysis/six studies istradefylline
20 and 40 mg/day of
istradefylline revealed
significantly decreased durations
of “off episodes” in PD patients
3.2. Animal Studies/Molecular Pathways
Older studies have already demonstrated neuroprotective effects of caffeine in PD
mouse models [68]. In line with these previous encouraging results, Luan et al. demon-
strated that chronic caffeine treatment reduced the effect of intra-striatal injected human
A53T α-Synuclein fibrils in mice [69]. Caffeine was administered seven days before the in-
jection and applied for 120 days at concentrations of ~0.4–2 mg/L. They found significantly
decreased inclusion of α-Synuclein in the striatum of the caffeine treated mice. Further-
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more, apoptosis, microglial activation and astrogliosis were significantly reduced [69]. A
similar study used 52 rats with a control group, a PD model group—generated by injecting
1.5 mg/kg rotenone intraperitoneally (i.p.) for 45 days—and two caffeine groups. One of
the caffeine groups was injected with 30 mg/kg caffeine i.p. in addition to the administered
rotenone for 45 days, whereas the other group was treated with caffeine after the induction
of PD via rotenone. The study revealed that co-treatment and post-treatment with caffeine
in the intoxicated rats enhanced the dysfunction of rotenone-induced motor symptoms by
recovering dopamine levels in the midbrain and striatum. In addition, caffeine improved
the antioxidant effect by reducing rotenone-induced lipid peroxidation and superoxide
dismutase activity in the striatum and midbrain. Furthermore, the data revealed reduced
rotenone-induced TNF-α activity in the caffeine groups indicating an anti-inflammatory
effect of caffeine. Caffeine protection and treatment restored open field test parameters,
forelimb hanging test and traction test to nearly control group values. Histopathological
investigation revealed a degeneration of neurons and presence of Lewy bodies in the
rotenone-induced PD group, which was prevented in both caffeine groups with a more
prominent effect in the caffeine protected group [70]. Pardo et al. demonstrated in another
animal study that the naturally occurring methylxanthine theophylline can reverse motor
symptoms in rats. In this study theophylline reversed locomotion, catalepsy and tremulous
jaw movement (resembling parkinsonian tremor) induced by pimozide, a D2 dopamine
antagonist [71]. In conclusion, these studies show a link for caffeine and other methylxan-
thines acting as A2A receptor antagonists with a decreased risk for PD and modification of
progression, indicating new adenosine receptor ligands might be encouraging targets in
treating PD. In a study by Rohilla et al. newly synthesized xanthine derivates as selective
AR antagonists were analyzed. Evaluation of the antiparkinsonian effect in the study
was carried out by inducing catatonia in rats with perphenazine. Most xanthines signifi-
cantly lowered the catatonic score compared to control. The most potent antiparkinsonian
effect was found for the methylxanthine RB-531 (8-[3-(3-Chloropropxy)]-1,3-dipropyl-7-
methylxanthine), showing a similar response as the standard treatment L-DOPA [72]. The
abovementioned studies and their outcomes are summarized in Figure 2 and Table 4.
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reduced inclusion of α-synuclein,
apoptosis, microglial activation and
astrogliosis after caffeine treatment
Khadrawy et al. [70] 2017 rotenenoe induced PDmice model caffeine
recovering dopamine levels in
midbrain and striatum ameliorating
motor symptoms, antioxidative and
anti-inflammatory effect of caffeine,
prevention of neurodegeneration
through less lewy bodies
Pardo et al. [71] 2020 pimozide induced PDmice model theophylline
reversed locomotion, catalepsy and
tremulous jaw movement
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most xanthines significantly lowered
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shows a similar response as L-DOPA
4. Multiple Sclerosis
4.1. Epidemiological and Clinical Studies
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system
(CNS) where the immune system impairs the myelin sheath that covers nerve fibers.
Thus, communication between the CNS and the peripheral nervous system (PNS) is
damaged resulting in a potentially disabling neurologic disease. The underlying cause
of MS is unclear, however epidemiological studies have shown that low serum levels of
Vitamin D, smoking and Epstein-Barr-Virus infections play a role in the development of
the disease [73,74].
Unlike in PD or AD, a recent study from Lu et al. revealed no association between
coffee consumption and the risk of MS [75] (see Table 5).
Table 5. Summary of recent clinical studies investigating the relationship between methylxanthines
and multiple sclerosis (MS). n: sample size.
Author Year Type of Study/n Substance Outcome
Lu et al. [75] 2020
mendelian randomization
study/14,802 MS subjects
vs. 26,703 healthy controls
coffee
The authors state that
coffee consumption and
the risk of MS might not
be causally associated
4.2. Animal Studies/Molecular Pathways
Although no clear association between methylxanthines and the risk for MS has been
reported, animal studies with caffeine have shown an interesting therapeutical poten-
tial of methylxanthines in respect to MS, as summarized in Figure 3 and Table 6. One
study demonstrated the neuroprotective effect of caffeine in experimental autoimmune
encephalomyelitis (EAE) rats. An adenosine receptor mediated shift from Th1 to Th2
cell cytokine function revealed caffeine as a potential immunomodulatory drug [76]. A
more recent study by Duman et al. discovered that theophylline enhanced CNS and PNS
remyelination by increasing HDAC2, SOX10 and MBP protein levels in young adults and
old mice after inducing a focal demyelinating lesion in the spinal cord. The increased
remyelination efficiency of theophylline only occurred in the lesion site [77]. Ruiz-Perera
et al. also discovered a potential link between methylxanthines and MS. In their study,
the authors found that pentoxifylline completely shifted human neuronal stem cells to the
oligodendroglial fate by inhibiting the c-REL pathway [78].
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Table 6. Summary of recent animal and cell culture studies investigating the relationship between methylxanthines and
Multiple Sclerosis (MS).
Author Year Used Model Substance Outcome
Duman et al. [77] 2020
lysolecithin induced
demyelination lesion in the
spinal cord of mice
theophylline
increased remyelination
efficiency within lesion side via
through increase of HADC2,
SOX10 and MBP protein levels
Ruiz-Perera et al. [78] 2020 human neuronal stem cells pentoxifylline
through inhibition of the c-REL
pathway pentoxifylline shifted
stem cell differentiation to
oligodendrioglial cells
5. Conclusions
In summary, the recent literature provides further evidence for beneficial effects of
methylated xanthine-derivatives like caffeine, theobromine, theophylline, pentoxifylline
and propentofylline on pathological processes leading to neurodegenerative diseases,
including Alzheimer´s disease, Parkinson´s disease and multiple sclerosis. However,
recent clinical trials show a clearer association between methylxanthine and PD than AD
or MS. Nevertheless, in respect to AD, several recent experi ental studies have suggested
molecular mechanisms by which methylxanthines could mediate protective effects. Further
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studies are needed to clarify the suggested relationship between methylated xanthine
variants and the pathomechanisms present in MS in more detail.
The physiological plasma levels of caffeine (and its naturally occurring metabolites)
after daily intake of moderate amounts of coffee are not sufficient to trigger all the observed
effects and higher levels that can be reached by pharmaceutical intake. It can also have
unintended side effects like tremors, palpitations and arrhythmias, therefore the use of syn-
thetic xanthine derivatives becomes more and more important. Regarding PD, the caffeine
analogue istradefylline has potential to be an application of a synthetic methylxanthine for
the treatment of a neurodegenerative disorder. Moreover, it is currently under investiga-
tion for the treatment of AD. These findings show that examining and synthesizing such
xanthine derivatives, and moreover analyzing them in clinical trials, could be a promising
approach in therapies of neurodegenerative diseases.
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